Accurate Biotechnology Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Guangzhou Guangdong China

Primary Industry

Biotechnology

About

Established in 2016 and based in Macau, China, Accurate Biotechnology is a biomedical company that engages in the clinical individualized treatment of or-ganoids, drug development, and regenerative medicine. The company is headquartered in Guangzhou, with R&D centers in Beijing, Shanghai and Milan, and has three holding companies. The company's chief scientist officer , Professor Chuxia Deng, was a member of the 2007 Nobel Prize winning team in physiology and medicine. The company's self-developed products include Peixinan, an organoid-targeted drug sensitivity assay, Peixinkang, an individualized tumor companion diagnostic combining organoid drug sensitivity technology with second-generation sequencing technology, and Accuroid™, an organ culture and organoid drug sensitivity screening product. Their products are used in the field of scientific research, drug development, clinical application and precision tumor therapy.

Current Investors

Binhai Fund Management, Qudao Asset Management, Fortune Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.3dbudcare.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.